AURORA, Colo.--(BUSINESS WIRE)--Cerebral Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative treatments for neurological diseases, has appointed Stephen J. Farr, PhD as Chairman of the board of directors. Dr. Farr is the Co-Founder, President, and Chief Executive Officer of Zogenix, a biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases.
“Dr. Farr’s experience in CNS drug development and advanced drug delivery will provide valuable direction to Cerebral Therapeutics as it launches its Phase 2 trial of CT-010 for refractory epilepsy and builds out its pipeline of drugs for site specific administration to the CNS,” said Dan Abrams, M.D., Chief Executive Officer of Cerebral Therapeutics. “The company is grateful to Warren Lammert who served as the Board Chair during the company’s formative years and provided meaningful leadership for our growth. We also warmly welcome Dr. Stephen Collins to the board as he brings extensive CNS product development experience with a special focus on epilepsy.”
Dr. Farr has served as the Chief Executive Officer of Zogenix since April 2015, pivoting the company’s strategy towards the development and commercialization of drugs that treat rare disorders, which recently resulted in the U.S. approval of FINTEPLA for the treatment of seizures associated with Dravet syndrome, a serious childhood development epileptic encephalopathy. Prior to 2015, Dr. Farr also served as the President and Chief Operating Officer at Zogenix since its founding in 2006, leading the development and FDA approval of the company’s first two drug products. Dr. Farr has served on the Cerebral Therapeutics board since 2018.
“Cerebral’s novel approach to brain targeted delivery, unique team with extensive drug and device experience, and focus on unmet needs in CNS is exciting and I’m pleased to serve in this role as Board Chair. I look forward to seeing our programs advance and to bringing new therapies to patients with epilepsy and other CNS disorders,” said Farr.
Cerebral also appointed to the board of directors Stephen D. Collins, M.D., PhD. Dr. Collins has led or had senior leadership positions in multiple pharmaceutical and biotech companies in a wide range of therapeutic areas resulting in over a dozen approved drugs and multiple company acquisitions. Currently, he is Executive Chairman of Xalud Therapeutics a biologics based, anti-inflammatory focused company in Phase 2 clinical studies of a novel platform.
About Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to improving the lives of patients living with severe refractory epilepsy and other uncontrollable neurological diseases. Founded by experts in the fields of neurology, neurosurgery, and drug delivery, Cerebral Therapeutics is pioneering the development of drug-device combination therapies that enable precise targeted delivery to the central nervous system. The goal of this novel approach is to maximize efficacy while greatly reducing systemic drug exposure and enhancing drug regimen compliance. Cerebral Therapeutics’ intracerebroventricular infusion therapy may offer a more efficacious and reliable approach to treating neurological diseases for which oral medications are not able to achieve adequate control and/or are limited by systemic toxicities.
